杏林製薬の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2022/01/27 | 1,800 | 1,802 | 1,776 | 1,792 | -24 | -1.3% | 153,300 |
2022/01/26 | 1,835 | 1,835 | 1,810 | 1,816 | -22 | -1.2% | 49,100 |
2022/01/25 | 1,850 | 1,850 | 1,820 | 1,838 | -7 | -0.4% | 80,700 |
2022/01/24 | 1,803 | 1,849 | 1,803 | 1,845 | +24 | +1.3% | 79,800 |
2022/01/21 | 1,791 | 1,827 | 1,780 | 1,821 | +22 | +1.2% | 114,100 |
2022/01/20 | 1,826 | 1,826 | 1,792 | 1,799 | -16 | -0.9% | 122,700 |
2022/01/19 | 1,809 | 1,822 | 1,798 | 1,815 | -11 | -0.6% | 85,300 |
2022/01/18 | 1,847 | 1,852 | 1,825 | 1,826 | ±0 | ±0% | 82,800 |
2022/01/17 | 1,843 | 1,843 | 1,815 | 1,826 | -9 | -0.5% | 29,900 |
2022/01/14 | 1,826 | 1,835 | 1,811 | 1,835 | +8 | +0.4% | 77,300 |
2022/01/13 | 1,820 | 1,831 | 1,813 | 1,827 | +5 | +0.3% | 70,500 |
2022/01/12 | 1,815 | 1,838 | 1,810 | 1,822 | +14 | +0.8% | 54,700 |
2022/01/11 | 1,813 | 1,813 | 1,786 | 1,808 | +9 | +0.5% | 52,700 |
2022/01/07 | 1,801 | 1,812 | 1,781 | 1,799 | -3 | -0.2% | 71,200 |
2022/01/06 | 1,820 | 1,834 | 1,799 | 1,802 | -29 | -1.6% | 66,100 |
2022/01/05 | 1,849 | 1,849 | 1,820 | 1,831 | -7 | -0.4% | 75,900 |
2022/01/04 | 1,842 | 1,848 | 1,826 | 1,838 | -8 | -0.4% | 78,700 |
2021/12/30 | 1,845 | 1,850 | 1,840 | 1,846 | +1 | +0.1% | 51,100 |
2021/12/29 | 1,838 | 1,857 | 1,829 | 1,845 | ±0 | ±0% | 75,800 |
2021/12/28 | 1,828 | 1,845 | 1,816 | 1,845 | +22 | +1.2% | 104,400 |
2021/12/27 | 1,815 | 1,824 | 1,791 | 1,823 | +12 | +0.7% | 68,500 |
2021/12/24 | 1,813 | 1,818 | 1,800 | 1,811 | +11 | +0.6% | 78,100 |
2021/12/23 | 1,810 | 1,810 | 1,787 | 1,800 | -10 | -0.6% | 78,900 |
2021/12/22 | 1,798 | 1,810 | 1,790 | 1,810 | +21 | +1.2% | 97,600 |
2021/12/21 | 1,796 | 1,799 | 1,782 | 1,789 | +15 | +0.8% | 78,400 |
2021/12/20 | 1,783 | 1,794 | 1,773 | 1,774 | -25 | -1.4% | 63,700 |
2021/12/17 | 1,797 | 1,808 | 1,786 | 1,799 | -7 | -0.4% | 131,800 |
2021/12/16 | 1,815 | 1,816 | 1,790 | 1,806 | +14 | +0.8% | 84,700 |
2021/12/15 | 1,790 | 1,803 | 1,783 | 1,792 | -7 | -0.4% | 62,300 |
2021/12/14 | 1,782 | 1,803 | 1,777 | 1,799 | +34 | +1.9% | 98,600 |
2021/12/13 | 1,800 | 1,800 | 1,761 | 1,765 | -28 | -1.6% | 64,400 |
2021/12/10 | 1,789 | 1,804 | 1,776 | 1,793 | +4 | +0.2% | 131,900 |
2021/12/09 | 1,804 | 1,809 | 1,787 | 1,789 | -6 | -0.3% | 208,400 |
2021/12/08 | 1,783 | 1,798 | 1,773 | 1,795 | +13 | +0.7% | 149,800 |
2021/12/07 | 1,743 | 1,783 | 1,741 | 1,782 | +52 | +3% | 113,200 |
2021/12/06 | 1,737 | 1,755 | 1,729 | 1,730 | -12 | -0.7% | 110,700 |
2021/12/03 | 1,692 | 1,742 | 1,685 | 1,742 | +59 | +3.5% | 124,000 |
2021/12/02 | 1,663 | 1,693 | 1,663 | 1,683 | +11 | +0.7% | 96,100 |
2021/12/01 | 1,675 | 1,675 | 1,662 | 1,672 | -16 | -0.9% | 100,700 |
2021/11/30 | 1,689 | 1,721 | 1,683 | 1,688 | -12 | -0.7% | 198,800 |
2021/11/29 | 1,692 | 1,716 | 1,692 | 1,700 | -8 | -0.5% | 86,900 |
2021/11/26 | 1,716 | 1,716 | 1,693 | 1,708 | -12 | -0.7% | 86,000 |
2021/11/25 | 1,713 | 1,720 | 1,700 | 1,720 | ±0 | ±0% | 104,600 |
2021/11/24 | 1,730 | 1,748 | 1,716 | 1,720 | -9 | -0.5% | 75,800 |
2021/11/22 | 1,719 | 1,730 | 1,707 | 1,729 | -1 | -0.1% | 51,700 |
2021/11/19 | 1,736 | 1,742 | 1,720 | 1,730 | -12 | -0.7% | 69,700 |
2021/11/18 | 1,746 | 1,746 | 1,718 | 1,742 | -13 | -0.7% | 106,100 |
2021/11/17 | 1,785 | 1,785 | 1,753 | 1,755 | -30 | -1.7% | 69,100 |
2021/11/16 | 1,797 | 1,809 | 1,779 | 1,785 | -21 | -1.2% | 79,700 |
2021/11/15 | 1,818 | 1,820 | 1,796 | 1,806 | +3 | +0.2% | 66,500 |
801~
850
件表示中 / 3694件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
杏林製薬 | 146,400円 | +8.8% | +99.9% | 3.55% | 9.35倍 | 0.65倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
ジーエヌアイ | 231,600円 | +21.7% | +999.9% | 0.00% | 9.64倍 | 3.19倍 |
|
中国の特発性肺線維症で高シェア、肺線維症後続薬進出。米国で人工骨も。米中に研究開発機能 |
持田薬 | 305,000円 | +3.0% | +27.5% | 2.62% | 19.31倍 | 0.84倍 |
|
医薬中堅。高脂血症薬、降圧薬など循環器系得意。婦人科系にも強み。消化器系育成。化粧品も |
栄研化 | 220,600円 | +0.4% | -8.4% | 2.40% | 28.32倍 | 1.60倍 |
|
臨床検査薬大手。便潜血検査試薬(FIT)はシェア7割。尿検査(ウロ)、遺伝子検査も育成 |
ネクセラファーマ | 87,800円 | +20.3% | - | 0.00% | 154.85倍 | 1.15倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
市場注目の銘柄
チャート関連のコラム